Bioventus Inc.

BVS Healthcare Medical Devices

Bioventus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $568.1 million, down 0.91% from fiscal 2024.

Revenue
+2.73%
EPS
+100.6%
Free cash flow
−31.4%
Total debt
−28.8%

Quarter to September 2026, against a year earlier

10.68 0.00 0.00%
Market cap
$899.9M
P/E
12.3×
Fwd P/E
17.2×
Dividend yield
—
F-score
8/9
Altman Z
1.26
Beneish M
−2.77
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
Piotroski F-Score

+8 more TTM periods

8 8 8 7
ROE
10.98% 13.57% 22.75% 22.96%
ROA
3.22% 4.24% 7.89% 8.33%
ROIC
7.16% 7.64% 7.34% 7.22%
Return on Tangible Assets
16.92% 23.15% 43.36% 44.90%
Average Days of Receivables
82.44 76.33 86.82 86.15
Free Cash Flow per Share
1.08 1.50 1.39 1.24
Free Cash Flow
72.11 100.63 94.29 84.99
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026